{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:57:18Z","timestamp":1789689438837,"version":"4.0.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cellular therapies have been cornerstones of the treatment of mantle cell lymphoma (MCL) for decades and have helped to improve the outcome of this formerly very unfavourable B-cell lymphoma considerably. Current established roles of cellular therapies include autologous hematopoietic cell transplantation (HCT) as part of first-line therapy, chimeric antigen receptor-engineered T-cells (CART) for relapsed\/refractory MCL, and allogeneic HCT for settings in which CARTs have failed or are unavailable. Therapeutic innovations have recently entered the MCL treatment landscape and are moving upstream in treatment algorithms, challenging the existing management principles. The purpose of this paper is to give some guidance regarding how to best use cellular therapies in this increasingly complex environment. Due to differences in CART labels, available non-cellular treatment options, and philosophy between the American and the European health systems, we found it reasonable to contrast the American and European perspectives on defined standard scenarios, which are often overlapping but show discrepancies in some important aspects.<\/jats:p>","DOI":"10.1038\/s41409-025-02599-x","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T20:34:06Z","timestamp":1744662846000},"page":"759-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"2599_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bjc.1980.27","volume":"41","author":"G Tolksdorf","year":"1980","unstructured":"Tolksdorf G, Stein H, Lennert K. Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes). Br J Cancer. 1980;41:168\u201382.","journal-title":"Br J Cancer"},{"key":"2599_CR2","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","volume":"16","author":"W Hiddemann","year":"1998","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, Woltjen HH, Kreuser ED, Trumper L, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16:1922\u201330.","journal-title":"J Clin Oncol"},{"key":"2599_CR3","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"2599_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565\u201375.","journal-title":"Lancet"},{"key":"2599_CR5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250\u201360.","journal-title":"N Engl J Med"},{"key":"2599_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"2599_CR7","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.20.02287","volume":"38","author":"P Jain","year":"2020","unstructured":"Jain P, Dreyling M, Seymour JF, Wang M. High-risk mantle cell lymphoma: definition, current challenges, and management. J Clin Oncol. 2020;38:4302\u201316.","journal-title":"J Clin Oncol"},{"key":"2599_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903\u201310.","journal-title":"Blood"},{"key":"2599_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.14870","volume":"179","author":"S Rule","year":"2017","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179:430\u20139.","journal-title":"Br J Haematol"},{"key":"2599_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386:48\u2013494.","journal-title":"N Engl J Med"},{"key":"2599_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183:578\u201387.","journal-title":"Br J Haematol"},{"key":"2599_CR12","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","volume":"5","author":"CW Eskelund","year":"2021","unstructured":"Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, Raty R, Gjerdrum LMR, et al. Detailed long-term follow-up of patients who relapsed after the nordic mantle cell lymphoma trials: MCL2 and MCL3. Hemasphere. 2021;5:e510.","journal-title":"Hemasphere"},{"key":"2599_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/bloodadvances.2023011152","volume":"8","author":"A Tivey","year":"2024","unstructured":"Tivey A, Shotton R, Eyre TA, Lewis D, Stanton L, Allchin R, et al. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study. Blood Adv. 2024;8:1209\u201319.","journal-title":"Blood Adv"},{"key":"2599_CR14","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjh.15643","volume":"185","author":"C Visco","year":"2019","unstructured":"Visco C, Tisi MC, Evangelista A, Di RA, Zoellner AK, Zilioli VR, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185:940\u20134.","journal-title":"Br J Haematol"},{"key":"2599_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood-2023-173615","volume":"142","author":"C Sarkozy","year":"2023","unstructured":"Sarkozy C, Chartier L, Ribrag V, Gressin R, Geisler C, Kluin-Nelemans HC. et al.Validation of POD24 as a robust early clinical end point of poor survival in mantle cell lymphoma from 1280 patients on clinical trials. Blood. 2023;142:299\u2013301.","journal-title":"Blood"},{"key":"2599_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/oxfordjournals.annonc.a059156","volume":"6","author":"DA Stewart","year":"1995","unstructured":"Stewart DA, Vose JM, Weisenburger DD, Anderson JR, Ruby EI, Bast MA, et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol. 1995;6:263\u20136.","journal-title":"Ann Oncol"},{"key":"2599_CR17","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"IF Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, K\u00f6rbling M, et al. Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803\u20139.","journal-title":"J Clin Oncol"},{"key":"2599_CR18","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non-randomized phase-II multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687\u201393.","journal-title":"Blood"},{"key":"2599_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","volume":"32","author":"TS Fenske","year":"2013","unstructured":"Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2013;32:273\u201381.","journal-title":"J Clin Oncol"},{"key":"2599_CR20","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le GS, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv62\u2013iv71.","journal-title":"Ann Oncol"},{"key":"2599_CR21","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","volume":"56","author":"PN Munshi","year":"2021","unstructured":"Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transpl. 2021;56:2911\u201321.","journal-title":"Bone Marrow Transpl"},{"key":"2599_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2014.223","volume":"29","author":"S Robinson","year":"2015","unstructured":"Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, et al. The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29:464\u201373.","journal-title":"Leukemia"},{"key":"2599_CR23","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u2013306.","journal-title":"Lancet"},{"key":"2599_CR24","doi-asserted-by":"crossref","unstructured":"Wagner-Johnston N, Jegede O, Spurgeon SE, Maddocks KJ, Yang DT, Romanoff J et al. Addition or substitution of acalabrutinib in intensive frontline chemoimmunotherapy for patients <70 years old with mantle cell lymphoma: outcomes of the 3-arm randomized phase II intergroup trial ECOG-ACRIN EA4181. Blood (ASH Annual Meeting Abstracts) 2024;144:236.","DOI":"10.1182\/blood-2024-194641"},{"key":"2599_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41:555\u201367.","journal-title":"J Clin Oncol"},{"key":"2599_CR26","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41:2594\u2013606.","journal-title":"J Clin Oncol"},{"key":"2599_CR27","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988\u201397.","journal-title":"J Clin Oncol"},{"key":"2599_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood.2020008727","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood. 2021;137:877\u201387.","journal-title":"Blood"},{"key":"2599_CR29","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1182\/bloodadvances.2023012424","volume":"8","author":"M Wang","year":"2024","unstructured":"Wang M, Robak T, Maddocks KJ, Phillips T, Smith SD, Gallinson D, et al. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv. 2024;8:4539\u201348.","journal-title":"Blood Adv"},{"key":"2599_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.23.02470","volume":"43","author":"TJ Phillips","year":"2025","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, trneny M, et al. Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study. J Clin Oncol. 2025;43:318\u201328.","journal-title":"J Clin Oncol"},{"key":"2599_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","volume":"21","author":"MD Stanchina","year":"2024","unstructured":"Stanchina MD, Montoya S, Danilov AV, Castillo JJ, Alencar AJ, Chavez JC, et al. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024;21:867\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"2599_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","volume":"26","author":"M Wang","year":"2025","unstructured":"Wang M, Jurczak W, trneny M, Belada D, Wrobel T, Ghosh N, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025;26:200\u201313.","journal-title":"Lancet Oncol"},{"key":"2599_CR33","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue M-H, Beldjord K, B\u00f6ttcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215\u201323.","journal-title":"Blood"},{"key":"2599_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410\u20138.","journal-title":"Br J Haematol."},{"key":"2599_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/hematology.2024000546","volume":"2024","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Dreyling M. To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL. Hematol Am Soc Hematol Educ Program. 2024;2024:42\u201347.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2599_CR36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","volume":"24","author":"V Jurinovic","year":"2018","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of two randomized trials from the German Low-Grade Lymphoma Study Group. Biol Blood Marrow Transpl. 2018;24:1172\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR37","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1182\/bloodadvances.2023010757","volume":"7","author":"JN Gerson","year":"2023","unstructured":"Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv. 2023;7:7393\u2013401.","journal-title":"Blood Adv"},{"key":"2599_CR38","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:1046\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.bbmt.2017.10.029","volume":"24","author":"YD Tseng","year":"2018","unstructured":"Tseng YD, Stevenson PA, Cassaday RD, Cowan A, Till BG, Shadman M, et al. Total body irradiation is safe and similarly effective as chemotherapy-only conditioning in autologous stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transpl. 2018;24:282\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1200\/JCO.22.01780","volume":"41","author":"O Hermine","year":"2023","unstructured":"Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, et al. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the european mantle cell lymphoma network. J Clin Oncol. 2023;41:479\u201384.","journal-title":"J Clin Oncol"},{"key":"2599_CR41","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/annonc\/mdu440","volume":"25","author":"I El-Najjar","year":"2014","unstructured":"El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, et al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem cell transplantation in the modern era. A retrospective study of the EBMT Lymphoma Working Party. Ann Oncol. 2014;25:2224\u20139.","journal-title":"Ann Oncol"},{"key":"2599_CR42","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.bbmt.2015.05.010","volume":"21","author":"A Urbano-Ispizua","year":"2015","unstructured":"Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, et al. The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen. Biol Blood Marrow Transpl. 2015;21:1746\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transpl. 2018;53:617\u201324.","journal-title":"Bone Marrow Transpl"},{"key":"2599_CR44","doi-asserted-by":"crossref","unstructured":"Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann BN et al. Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma. Blood Cancer Discov. 2025.","DOI":"10.1158\/2643-3230.c.7801750"},{"key":"2599_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2013;19:625\u201331.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR46","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/bjh.15721","volume":"184","author":"RJ Lin","year":"2019","unstructured":"Lin RJ, Ho C, Hilden PD, Barker JN, Giralt SA, Hamlin PA, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019;184:1006\u201310.","journal-title":"Br J Haematol."},{"key":"2599_CR47","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","volume":"25","author":"S Dietrich","year":"2014","unstructured":"Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014;25:1053\u20138.","journal-title":"Ann Oncol"},{"key":"2599_CR48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjh.16182","volume":"188","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma\u2014a LWP-EBMT study. Br J Haematol. 2020;188:745\u201356.","journal-title":"Br J Haematol."},{"key":"2599_CR49","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.2217\/fon-2016-0146","volume":"12","author":"MA Kharfan-Dabaja","year":"2016","unstructured":"Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, et al. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. Future Oncol. 2016;12:2631\u201342.","journal-title":"Future Oncol."},{"key":"2599_CR50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamaoncol.2020.1278","volume":"6","author":"N Ghosh","year":"2020","unstructured":"Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, et al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant. JAMA Oncol. 2020;6:1011\u20138.","journal-title":"JAMA Oncol"},{"key":"2599_CR51","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","volume":"22","author":"TS Fenske","year":"2016","unstructured":"Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, et al. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients. Biol Blood Marrow Transpl. 2016;22:1543\u201351.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR52","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2015.22","volume":"50","author":"S Garciaz","year":"2015","unstructured":"Garciaz S, Castagna L, Bouabdallah R, Furst S, Bramanti S, Coso D, et al. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transpl. 2015;50:865\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2599_CR53","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","volume":"127","author":"AS Kanate","year":"2016","unstructured":"Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. Blood. 2016;127:938\u201347.","journal-title":"Blood"},{"key":"2599_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41409-020-0976-4","volume":"56","author":"L Selberg","year":"2021","unstructured":"Selberg L, Stadtherr P, Dietrich S, Tran TH, Luft T, Hegenbart U, et al. The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. Bone Marrow Transpl. 2021;56:30\u201337.","journal-title":"Bone Marrow Transpl"},{"key":"2599_CR55","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.bbmt.2014.07.009","volume":"20","author":"O Ringden","year":"2014","unstructured":"Ringden O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transpl. 2014;20:1777\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR56","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.bbmt.2020.04.025","volume":"26","author":"ML Schubert","year":"2020","unstructured":"Schubert ML, Dietrich S, Stilgenbauer S, Schmitt A, Pavel P, Kunz A, et al. Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2020;26:1575\u201380.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41375-024-02467-5","volume":"39","author":"G Orti","year":"2025","unstructured":"Orti G, Peczynski C, Boreland W, O\u2019Reilly M, von BM, Balduzzi A, et al. Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study. Leukemia. 2025;39:431\u20137.","journal-title":"Leukemia"},{"key":"2599_CR58","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ajh.27056","volume":"98","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023;98:1699\u2013710.","journal-title":"Am J Hematol"},{"key":"2599_CR59","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med 2024;30:2667\u201378.","journal-title":"Nat Med"},{"key":"2599_CR60","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024;42:1146\u201357.","journal-title":"J Clin Oncol"},{"key":"2599_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01755-5","volume":"22","author":"Z Huang","year":"2023","unstructured":"Huang Z, Chavda VP, Bezbaruah R, Dhamne H, Yang DH, Zhao HB. CAR T-Cell therapy for the management of mantle cell lymphoma. Mol Cancer. 2023;22:67.","journal-title":"Mol Cancer"},{"key":"2599_CR62","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med 2024;390:2047\u201360.","journal-title":"N Engl J Med"},{"key":"2599_CR63","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","volume":"8","author":"AJ Lamble","year":"2024","unstructured":"Lamble AJ, Schultz LM, Nguyen K, Hsieh EM, McNerney K, Rouce RH, et al. Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024;8:3544\u20138.","journal-title":"Blood Adv"},{"key":"2599_CR64","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"391","author":"G Kobbe","year":"2024","unstructured":"Kobbe G, Bruggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, et al. Aggressive Lymphoma after CD19 CAR T-Cell Therapy. N Engl J Med 2024;391:1217\u201326.","journal-title":"N Engl J Med"},{"key":"2599_CR65","doi-asserted-by":"crossref","unstructured":"Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat Med. 2025.","DOI":"10.1038\/s41591-025-03717-4"},{"key":"2599_CR66","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Cordas Dos Santos DM, et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5517 lymphoma and myeloma patients. Clin Cancer Res. 2024;30:4690\u20134700.","journal-title":"Clin Cancer Res"},{"key":"2599_CR67","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","volume":"392","author":"SJ Harrison","year":"2025","unstructured":"Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, et al. CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma. N Engl J Med 2025;392:677\u201385.","journal-title":"N Engl J Med"},{"key":"2599_CR68","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024;143:1565\u201375.","journal-title":"Blood"},{"key":"2599_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","volume":"16","author":"AS Freedman","year":"1998","unstructured":"Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998;16:13\u201318.","journal-title":"J Clin Oncol"},{"key":"2599_CR70","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","volume":"22","author":"N Milpied","year":"1998","unstructured":"Milpied N, Gaillard F, Moreau P, Mah\u00e9 B, Souchet J, Rapp MJ, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transpl. 1998;22:645\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"2599_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.thj.6200007","volume":"1","author":"P Dreger","year":"2000","unstructured":"Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kr\u00f6ger N, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J. 2000;1:87\u201394.","journal-title":"Hematol J"},{"key":"2599_CR72","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/blood.2024023944","volume":"144","author":"C Sarkozy","year":"2024","unstructured":"Sarkozy C, Callanan M, Thieblemont C, Oberic L, Burroni B, Bouabdallah K, et al. Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma. Blood. 2024;144:262\u201371.","journal-title":"Blood"},{"key":"2599_CR73","doi-asserted-by":"crossref","unstructured":"Fenske TS, Wang XV, Till BG, Blum KA, Lunning M, Lazarus HM et al. Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma patients in first complete remission with Undetectable Minimal Residual Disease (uMRD): initial report from the ECOG-ACRIN EA4151 phase 3. Blood (ASH Annual Meeting Abstracts) 2024;144(Suppl. 1): LBA-6.","DOI":"10.1182\/blood-2024-212973"},{"key":"2599_CR74","first-page":"237","volume":"144","author":"M Ladetto","year":"2024","unstructured":"Ladetto M, Gutmair K, Doorduijn JK, Gine E, Jerkeman M, Walewski J, et al. Impact of rituximab maintenance added to ibrutinib-containing regimens with and without ASCT in younger, previously untreated MCl patients: an analysis of the triangle data embedded in the multiply project. Blood (ASH Annu Meet Abstr). 2024;144:237.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"2599_CR75","first-page":"240","volume":"144","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn JK, Gine E, Jerkeman M, Walewski J, Hutchings M, et al. Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. Blood (ASH Annu Meet Abstr). 2024;144:240.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"2599_CR76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood.2024025563","volume":"145","author":"A Kumar","year":"2025","unstructured":"Kumar A, Soumerai J, Abramson JS, Barnes JA, Caron P, Chhabra S, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025;145:497\u2013507.","journal-title":"Blood"},{"key":"2599_CR77","unstructured":"NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas 2.2025. 2025. NCCN Guidelines Version 2.2025. Mantle Cell Lymphoma. 24-3-2025. Ref Type: Online Source"},{"key":"2599_CR78","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kruger","year":"2014","unstructured":"Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO). Ann Hematol. 2014;93:1587\u201397.","journal-title":"Ann Hematol"},{"key":"2599_CR79","doi-asserted-by":"crossref","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transplant. 2025.","DOI":"10.1038\/s41409-025-02524-2"},{"key":"2599_CR80","first-page":"748","volume":"144","author":"T van Meerten","year":"2024","unstructured":"van Meerten T, Kersten MJ, Iacoboni G, Hess G, Mutsaers P, Garcia-Sancho AM, et al. Primary analysis of ZUMA-2 cohort 3: brexucabtagene autoleucel (Brexu-Cel) in patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) who were naive to bruton tyrosine kinase inhibitors. Blood (ASH Annu Meet Abstr). 2024;144:748.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"2599_CR81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.18378","volume":"199","author":"MA O\u2019Reilly","year":"2022","unstructured":"O\u2019Reilly MA, Sanderson R, Wilson W, Iyengar S, Lambert J, McCulloch R, et al. Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed\/refractory disease. Br J Haematol. 2022;199:40\u201344.","journal-title":"Br J Haematol"},{"key":"2599_CR82","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1002\/hem3.87","volume":"8","author":"MA O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly MA, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis. Hemasphere 2024;8:e87.","journal-title":"Hemasphere"},{"key":"2599_CR83","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/bjh.19961","volume":"206","author":"F Stella","year":"2025","unstructured":"Stella F, Chiappella A, Magni M, Bonifazi F, de PC, Musso M, et al. Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: results from CART-SIE study. Br J Haematol. 2025;206:644\u201351.","journal-title":"Br J Haematol"},{"key":"2599_CR84","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"2599_CR85","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1016\/S2352-3026(23)00307-1","volume":"10","author":"P Dreger","year":"2023","unstructured":"Dreger P, Corradini P, Gribben JG, Glass B, Jerkeman M, Kersten MJ, et al. CD19-directed CAR-T cells as first salvage therapy for large b-cell lymphoma: towards a rational approach. Lancet Haematol. 2023;10:e1006\u2013e1015.","journal-title":"Lancet Haematol"},{"key":"2599_CR86","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2023012255","volume":"8","author":"G Ahmed","year":"2024","unstructured":"Ahmed G, Alsouqi A, Szabo A, Samples L, Shadman M, Awan FT, et al. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024;8:3528\u201331.","journal-title":"Blood Adv"},{"key":"2599_CR87","first-page":"3745","volume":"109","author":"C Herbaux","year":"2024","unstructured":"Herbaux C, Bret C, Bachy E, Bories P, Di BR, Cuffel A, et al. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica. 2024;109:3745\u201350.","journal-title":"Haematologica"},{"key":"2599_CR88","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Martin-Lopez AA, Rejeski K, Kwon M, Jalowiec KA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol. 2024;42:205\u201317.","journal-title":"J Clin Oncol"},{"key":"2599_CR89","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbmt.2018.08.025","volume":"25","author":"C Kyriakou","year":"2019","unstructured":"Kyriakou C, Boumendil A, Finel H, Schmitz N, Andersen NS, Blaise D, et al. The impact of advanced patient age on mortality after allogeneic hematopoietic cell transplantation for non-Hodgkin\u2019s lymphoma: a retrospective study by the EBMT Lymphoma Working Party. Biol Blood Marrow Transpl. 2019;25:86\u201393.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2599_CR90","first-page":"734","volume":"142","author":"ML Wang","year":"2023","unstructured":"Wang ML, Assouline S, Kamdar M, Ghosh N, Naik S, Nakhoda S, et al. Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: initial results from a phase Ib\/II study. Blood (ASH Annu Meet Abstr). 2023;142:734.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"2599_CR91","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/hematology.2024000657","volume":"2024","author":"ZD Epstein-Peterson","year":"2024","unstructured":"Epstein-Peterson ZD, Palomba ML. T-cell-based therapies for treating relapsed or refractory mantle cell lymphoma. Hematol Am Soc Hematol Educ Program. 2024;2024:48\u201353.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2599_CR92","doi-asserted-by":"publisher","first-page":"eadj7970","DOI":"10.1126\/sciimmunol.adj7970","volume":"9","author":"M Kilian","year":"2024","unstructured":"Kilian M, Friedrich MJ, Lu KH, Vonhoren D, Jansky S, Michel J, et al. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance. Sci Immunol 2024;9:eadj7970.","journal-title":"Sci Immunol"},{"key":"2599_CR93","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood.2023022682","volume":"144","author":"BJ Brinkmann","year":"2024","unstructured":"Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, et al. CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models. Blood. 2024;144:784\u20139.","journal-title":"Blood"},{"key":"2599_CR94","doi-asserted-by":"crossref","unstructured":"Park JH, Palomba ML, Perica K, Devlin SM, Shah G, Dahi PB et al. Results from first-in-human phase I study of a novel CD19-1XX chimeric antigen receptor with calibrated signaling in large B-cell lymphoma. J Clin Oncol. 2025:JCO2402424.","DOI":"10.1200\/JCO-24-02424"},{"key":"2599_CR95","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330.","journal-title":"N Engl J Med"},{"key":"2599_CR96","doi-asserted-by":"crossref","unstructured":"Kolbe C, Kauer J, Brinkmann B, Dreger P, Huber W, Muller-Tidow C et al. Blocking the CD39\/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma. J Immunother. Cancer. 2025;13.","DOI":"10.1136\/jitc-2024-009245"},{"key":"2599_CR97","first-page":"4388","volume":"144","author":"M Wang","year":"2024","unstructured":"Wang M, Goy A, Munoz J, Locke FL, Jacobson CA, Hill BT, et al. Five-year outcomes of patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (Brexu-cel) in ZUMA-2 cohorts 1 and 2. Blood (ASH Annu Meet Abstr). 2024;144:4388.","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"2599_CR98","first-page":"96","volume":"47","author":"P Dreger","year":"2024","unstructured":"Dreger P, Schmidtmann I, Simon L, Vucinic V, Franke GN, Subklewe M, et al. Brexu-cel for r\/r MCL in the German\/Swiss real-world: beware of infections, but not of elderly patients. A GLA\/EMCL\/DRST\/SAKK analysis. Oncol Res Treat. 2024;47:96.","journal-title":"Oncol Res Treat."},{"key":"2599_CR99","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","volume":"54","author":"P Dreger","year":"2019","unstructured":"Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transpl. 2019;54:44\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"2599_CR100","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post-BTK inhibitor therapy. Br J Haematol. 2020;189:684\u20138.","journal-title":"Br J Haematol."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02599-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02599-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T15:02:06Z","timestamp":1749567726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02599-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2599"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02599-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PD: consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, Miltenyi (all to institution); speaker honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, Roche (all to institution); meeting attendance support from Beigene and Gilead; Participation on a Data Safety Monitoring Board for Novartis. PD is current chairman of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT). SA: Research support to institutions for clinical trials from Nektar, Merck, Xencor, Chimagen and Genmab, KITE\/Gilead, Janssen, Caribou. Consultant for ADC therapeutics, KITE\/Gilead, Genmab and BMS. SD: Roche: Advisory board; Kite\/Gilead: Advisory board. TS Fenske: Consulting: AbbVie, Adaptive Biotechnologies, Ipsen, Ono Pharmaceuticals. Speaking: AstraZeneca, Beigene, SeaGen. NG: Consulting\/Advisory: AbbVie, AstraZeneca, Beigene, BMS, Kite pharma, Genentech\/Roche, Incyte, Janssen, ADC Therapeutics, Galapagos, Ascentage Pharma. Research funding: Genentech\/Roche, AstraZeneca, AbbVie, Pepromene, Incyte, BMS. OH: Research support BMS, Blueprint, Consultant AB Science, Inatherys. KiTE\/Gilead, AstraZeneca. MH: Research Support\/Funding: ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, BMS, Kite, Genmab, CRISPR, Allovir, Caribou, Autolus, Forte Biosciences, Byondis, Daiichi Sankyo. Speaker\u2019s Bureau: AstraZeneca, ADC Therapeutics, BeiGene, Kite, Sobi. AB has no COIs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}